Breckenridge's generic Aromasin receives FDA OK
Breckenridge Pharmaceuticals has received the Food and Drug Administration's approval for its generic Aromasin (exemestane tablets). The generic of Pfizer's branded product was approved in 25-mg dosage strength.
The drug is used in women who are past menopause for the treatment of breast cancer.
Breckenridge said its generic Aromasin was developed in collaboration with Medikl and MSN Laboratories.
Exemestane tablets had a market value of $65 million during the twelve months ending Dec. 31, 2018, according to industry data.
The drug is used in women who are past menopause for the treatment of breast cancer.
Breckenridge said its generic Aromasin was developed in collaboration with Medikl and MSN Laboratories.
Exemestane tablets had a market value of $65 million during the twelve months ending Dec. 31, 2018, according to industry data.